SciSparc Ltd. (NASDAQ:SPRC) Short Interest Down 33.6% in November

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 260,200 shares, a drop of 33.6% from the October 31st total of 391,800 shares. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is currently 0.3 days. Approximately 2.5% of the shares of the company are sold short.

SciSparc Stock Down 2.9 %

Shares of NASDAQ:SPRC traded down $0.01 during midday trading on Friday, hitting $0.21. The stock had a trading volume of 156,131 shares, compared to its average volume of 1,551,149. SciSparc has a 1 year low of $0.21 and a 1 year high of $9.80. The stock has a 50 day moving average price of $0.23 and a two-hundred day moving average price of $0.51.

Institutional Investors Weigh In On SciSparc

A hedge fund recently bought a new stake in SciSparc stock. Renaissance Technologies LLC purchased a new position in shares of SciSparc Ltd. (NASDAQ:SPRC) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned 5.59% of SciSparc as of its most recent SEC filing. 25.06% of the stock is owned by institutional investors and hedge funds.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.